钙尔奇D联合重组人生长激素对特发性矮身材儿童骨代谢及血清IGF-1、25-(OH)D水平变化的影响研究

doi:10.11852/zgetbjzz2018-1525

中国儿童保健杂志 ›› 2019, Vol. 27 ›› Issue (7): 729-732.DOI: 10.11852/zgetbjzz2018-1525

钙尔奇D联合重组人生长激素对特发性矮身材儿童骨代谢及血清IGF-1、25-(OH)D水平变化的影响研究

唐秀平, 李玲, 闫保瑞

河南大学附属郑州颐和医院儿内科, 河南郑州 450003

收稿日期:2018-12-19 发布日期:2019-07-10 出版日期:2019-07-10
作者简介:唐秀平(1975-),女,河南人,副主任医师,本科学历,主要研究方向为儿童发育
基金资助:
河南省属预研项目(2014yy006)

Effect of Caltrate D combined with recombinant human growth hormone on bone metabolization indexes and serum levels of IGF-1,25-(OH)D in children with idiopathic short stature

TANG Xiu-ping, LI Ling, YAN Bao-rui

Zhengzhou Yihe Hospital Affiliated to Henan University,Zhengzhou,Henan 450003,China

Received:2018-12-19 Online:2019-07-10 Published:2019-07-10

摘要/Abstract

摘要： 目的探讨钙尔奇D辅助重组人生长激素(rhGH)治疗特发性矮身材(ISS)儿童的疗效及对骨代谢指标、胰岛素样生长因子-1(IGF-1)、25 羟维生素D[25-(OH)D]水平的影响。方法选取2015年1月-2017年6月本院收治的90例ISS患儿(ISS组),随机分为观察组与对照组,每组45例。另选同期性别、年龄相匹配的健康体检患儿45例作为正常组。对照组采用rhGH治疗,观察组采用rhGH加用钙尔奇D治疗。观察两组患儿治疗前及治疗后6、12个月身高(Ht)、骨龄(BA)、生长速度(GV)、身高均值标准差积分(HtSDS)、BA与生活年龄比值(BA/CA)、血清骨代谢指标[骨钙素(OC)、Ⅰ型前胶原氨基端延长肽(P1NP)]及25-(OH)D水平,并与45例健康正常儿童(正常组)进行比较。结果 ISS组的BA、Ht、GV、HtSDS、BA/CA及血清OC、PICP、IGF-1、25-(OH)D水平均显著低于正常组(P<0.05);治疗6、12个月,观察组的BA、Ht、GV、HtSDS、BA/CA及血清OC、PICP、IGF-1、25-(OH)D水平较治疗前显著提高(P<0.05),对照组的25-(OH)D水平无明显变化(P<0.05),且观察组的Ht、GV、HtSDS、HtSDS、及血清OC、PICP、IGF-1、25-(OH)D水平均显著高于对照组(P<0.05)。结论 ISS患儿存在骨代谢异常及IGF-1、25-(OH)D低水平现象,钙尔奇D辅助治疗可改善患儿的骨代谢状态并提高IGF-1、25-(OH)D水平,从而改善生长状况

关键词: 特发性矮身材, 钙尔奇D, 骨代谢, 胰岛素样生长因子-1, 25 羟维生素D

Abstract: Objective To analyze the efficacy of Calcium D combined with recombinant human growth hormone (rhGH) in the treatment of children with idiopathic short stature (ISS) and its effect on serum levels of bone metabolization indexes,insulin-like growth factor-1 (IGF-1),25-hydroxyvitamin D[25-(OH)D].Methods Totally 90 children with ISS (ISS group) in Zhengzhou Yihe Hospital Affiliated to Henan University from January 2015 to June 2017 were enrolled in this study,and were randomly divided into observation group and control group,with 45 cases in each group. The control group was treated with rhGH,the observation group was treated with rhGH and Calcium D. And 45 children taking physical examination matched by sex and age were selected as normal group. The height (Ht),bone age (BA),growth rate (GV),height standard deviation score (HtSDS),BA-to-chronological age (BA/CA) and serum levels of bone metabolization indexes[osteocalcin (OC),type I procollagen amino terminal prolongation peptide (P1NP)],IGF-1 and 25-(OH)D of observation group and control group were observed before treatment,6 and 12 months after treatment. The indexes were compared with normal group. Results The BA,Ht,GV,HtSDS,BA/CA and serum levels of OC,PICP,IGF-1,25-(OH)D in the ISS group were significantly lower than those in normal group (P<0.05). After 6 and 12 months of treatment,the BA,Ht,GV,HtSDS,BA/CA and serum levels of OC,PICP,IGF-1,25-(OH)D in the observation group significantly increased (P<0.05). However,the 25-(OH)D in control group did not change significantly (P>0.05). Moreover,the Ht,GV,HtSDS,HtSDS and serum levels of OC,PICP,IGF-1,25-(OH)D in the observation group were significantly higher than those in control group (P<0.05). Conclusions There is abnormal bone metabolism and low level of IGF-1 and 25-(OH)D in children with ISS. Calcium D adjuvant therapy can improve bone metabolization and increase serum levels of IGF-1 and 25-(OH)D,thereby improving growth development

Key words: idiopathic short stature, Calcium D, bone metabolization, insulin-like growth factor-1, 25-(OH)D

中图分类号:

R179

唐秀平, 李玲, 闫保瑞. 钙尔奇D联合重组人生长激素对特发性矮身材儿童骨代谢及血清IGF-1、25-(OH)D水平变化的影响研究[J]. 中国儿童保健杂志, 2019, 27(7): 729-732.

TANG Xiu-ping, LI Ling, YAN Bao-rui. Effect of Caltrate D combined with recombinant human growth hormone on bone metabolization indexes and serum levels of IGF-1,25-(OH)D in children with idiopathic short stature[J]. journal1, 2019, 27(7): 729-732.

参考文献

[1] 崔蕴璞,张铭涛,王新利.不同病因矮身材儿童TW2-R、C、T骨龄评分特征研究[J].中国当代儿科杂志,2015,17(5):464-468.
[2] 王慧燕,陶洪群,王玲莉,等.矮小症儿童GH激发试验及25-(OH)D水平的调查分析[J].医学研究杂志,2016,45(1):132-134.
[3] 曾婷,李红辉,严提珍,等.柳州市特发性矮小症瑶族学龄儿童维生素D和IGF-1水平与体格发育指标的相关性分析[J].职业与健康,2017,33(6):794-796.
[4] Cohen P,Rogol AD,Deal CL,et al.Consensus statement on the diagnosis and treatment of children with idiopathic short stature:a summary of the Growth Hormone Research Society,the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology Workshop[J].J Clin Endocrinol Metab,2008,93(11):4210-4217.
[5] 叶义言.中国儿童骨龄评分法[M].北京:人民卫生出版社,2005:84-151.
[6] 干冬梅,石小军.重组人生长激素对特发性矮小患儿症血清胰岛素样生长因子1与胰岛素样生长因子结合蛋白3水平的影响[J].中国生化药物杂志,2015,35(12):51-53.
[7] 彭艳,张崇建,王英,等.聚乙二醇重组生长激素治疗特发性矮小症儿童效果及对血清p53及p21waf/cip1表达的影响[J].中国儿童保健杂志,2018,26(6):587-589,593.
[8] 陈卫富,周爱萍,顾红丹,等.血清胰岛素样生长因子-1、胰岛素样生长因子结合蛋白-3及骨龄在矮小症儿童诊断中的价值[J].中国妇幼保健,2018,33(9):2047-2050.
[9] 鞠俊,刘雨田,郭广宏,等.5~14岁健康儿童青少年骨代谢指标年龄特征[J].中国实用儿科杂志,2017,32(10):759-763.
[10] 王斐,朱志颖,刘庆旭,等.生长激素治疗特发性矮小症前后骨转换指标变化的意义[J].中华实用儿科临床杂志,2016,31(20):1541-1545.
[11] 杨海英,王明月,董俊华,等.青春期前特发性矮小儿童IGF-1、骨代谢指标水平变化及相关分析[J].中国儿童保健杂志,2009,17(5):528-529,532.
[12] 刘冰,卢蕾阳,高飞,等.胰岛素样生长因子-1对甲状旁腺激素介导成骨细胞增殖及成骨活性的影响[J].中国骨质疏松杂志,2014,20(11):1298-1301.
[13] Gyon YH,Yun YJ,Kim YD,et al.Age at menarche and near final height after treatment with gonadotropin-releasing hormone agonist alone or combined with growth hormone in Korean girls with central precocious puberty[J].Clin Pediatr Endocrinol,2015,24(4):175-183.
[14] 王慧燕,陶洪群,王玲莉,等.矮小症儿童GH激发试验及25-(OH)D水平的调查分析[J].医学研究杂志,2016,45(1):132-134.
[15] 丘柳萍,阳文景,韦桂芬,等.口服维生素D对反复呼吸道感染矮身材儿童的骨代谢变化[J].临床检验杂志:电子版,2018,7(1):109-110.

钙尔奇D联合重组人生长激素对特发性矮身材儿童骨代谢及血清IGF-1、25-(OH)D水平变化的影响研究

Effect of Caltrate D combined with recombinant human growth hormone on bone metabolization indexes and serum levels of IGF-1,25-(OH)D in children with idiopathic short stature

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 12

编辑推荐

Metrics

[1]	张甜, 孙海玲, 张梅, 班博, 孙冰. 儿童营养不足与生长激素/胰岛素样生长因子-1相关性研究进展[J]. 中国儿童保健杂志, 2021, 29(7): 734-737.
[2]	张小龙, 张远达, 何华芬, 冀超玉, 杨旭, 任淑红. 丙戊酸、奥卡西平、左乙拉西坦单药治疗对学龄期癫痫患儿的疗效及骨代谢水平影响[J]. 中国儿童保健杂志, 2020, 28(3): 331-334.
[3]	陶娜, 张红红, 凌昱, 孙美媛, 王爱萍, 杨洋. 中枢性性早熟女童GnRHa治疗后骨代谢指标变化的临床研究[J]. 中国儿童保健杂志, 2019, 27(7): 717-719.
[4]	彭艳松, 邹芙蓉. 重组人生长激素对青春期前特发性矮身材儿童的生长速率、骨龄的影响及其量效-时效关系[J]. 中国儿童保健杂志, 2019, 27(11): 1228-1231.
[5]	洪晓文综述, 陈燕惠审校. 胰岛素样生长因子1在孤独症谱系障碍中的研究进展[J]. 中国儿童保健杂志, 2019, 27(1): 56-58.
[6]	周敬静, 张倩, 樊茂. 阻塞性睡眠呼吸暂停低通气综合征儿童血清生长因子表达的影响因素分析[J]. 中国儿童保健杂志, 2018, 26(6): 666-669.
[7]	桂林艳, 王璞. 青春期前特发性矮身材儿童的生长激素应用剂量研究[J]. 中国儿童保健杂志, 2018, 26(4): 451-452.
[8]	王琰华, 赵忻. GnGHa治疗对特发性中枢性性早熟女童血清P1NP、β-CTX、N-MID水平的影响及其临床意义[J]. 中国儿童保健杂志, 2017, 25(12): 1288-1289.
[9]	郑敏,潘莉珍,谭建强,蔡稔. 先天性甲状腺功能减低症治疗前后TSH、FT4、IGF-1水平的变化及与体格生长的关系[J]. 中国儿童保健杂志, 2013, 21(8): 793-795.
[10]	汪治华,闫晓莉,李小青,潘秋红. 性早熟女童血清IGF-1、瘦素检测及其临床价值探讨[J]. 中国儿童保健杂志, 2011, 19(9): 811-813.
[11]	阎雪,张亚男,皮亚雷,张会丰. 特发性中枢性性早熟女童血循环骨骼生长标志物NTproCNP水平测定[J]. 中国儿童保健杂志, 2011, 19(4): 303-305.
[12]	王新利,康新,关于红,齐婧,王朝红,张淑丽. 胰岛素样生长因子-1与健康婴儿生长速度及喂养关系分析[J]. 中国儿童保健杂志, 2011, 19(4): 354-357.